On April 14, Cue Biopharma announced that it will receive a $7.5 million milestone payment from Boehringer Ingelheim for the development of the CUE-501 compound. This payment follows the approval of the first compound for lead optimization under their collaboration agreement. The company could earn up to an additional $337.5 million in future milestone and royalty payments.
